

Guidance to R&D programmes: Scientific Advice and the PRIME network

2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency

Presented by Stiina Aarum on 8 March 2018 Product Development Scientific Support Department






This session:

Scientific advice and protocol assistance – Scope, value and current developments

- Parallel EMA/HTA scientific consultation
- Qualification of novel methodologies and biomarkers
- Modelling and simulation
- PRIME-Legal basis, value and experience so far



The typical long road of bringing medicines to patients



Regulatory provisions targeting the risk of development failure and the time to access:

Scientific advice

- Support to small/medium-sized enterprises
 - PRIority MEdicines scheme (PRIME)
 - Conditional marketing authorisation
 - Accelerated Assessment
 - Compassionate Use

Guidance to R&D programmes: Scientific Advice and the PRIME network


Scientific Advice

- Legal basis: According to Article 57-1 (n) of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004
- One of the tasks of the Agency is "advising undertakings on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of medicinal products".
- Prospective in nature- focusing on development strategies rather than preevaluation of data to support a MAA.
- Advising Applicants on the scientific requirements for marketing authorisation (MA):
 - Before the first MA: companies ask questions on manufacturing, non-clinical and clinical trials, risk-management plans, ways to develop generics, hybrids and biosimilars; significant benefit for orphan medicines; development in children etc.
 - Post-MA: extension of indication to different age groups and stages of the disease; different conditions; & safety aspects.
 Guidance to R&D programmes: Scientific Advice and the PRIME network



Scientific Advice Network

For human medicines, SA/PA is given by the Committee for Medicinal Products for Human Use (CHMP) on the recommendation of the Scientific Advice Working Party (SAWP).






Scientific Advice Working Party (SAWP)

- Experts from national authorities, universities and hospitals selected for expertise: e.g. oncology, cardiology, psychiatry, neurology, immunotherapy, gene and cell therapy, advanced therapies, pediatrics, geriatrics; quality, non—clinical and statistical methodologies.
- Joint members across Committees not only CHMP, but also Paediatrics, Orphan, Advanced Medicinal Products, PRAC
- Scientific and logistic support from EMA secretariat: medical doctors /pharmacists and assistants


SA can help to guide changes in the pivotal clinical development towards improved regulatory acceptability



 Obtaining and complying SA is strongly associated with a positive outcome of a MAA: almost 90% of those who obtain and follow SA receive a positive opinion compared to 40% for those who do not follow SA; *Hofer et al. 2015*



Scientific Advice main activity so far: scientific advice and protocol assistance



Guidance to R&D programmes: Scientific Advice and the PRIME network



N.C.


Parallel EMA/HTA scientific consultation

Starting point: Newly licensed medicines do not reach all patients in need Regulators and HTAs

- answer different questions
- have different requirements in terms of evidence
- Aim: decision makers come together early to discuss
 - the planned development including populations / comparators / design of trial /endpoints
 - the requirements for post-licensing evidence generation

Expectation: Optimised development plan → Improve access for patients

Reality check: from EU regulatory approval to national HTA/P&R decisions for oncology products



Martinalbo et al., Early access to cancer drugs in the EU. Ann Oncol 27: 96–105,8 20016018



Align regulatory and HTA thinking; what constitutes success?

- Tripartite understanding of roles, remits and standards
- Common language
- Common understanding of methodology
- Common understanding of science and methodology; different application?
- Evidence generation without undue delay: avoid sequential thinking
- Alignment of the perspectives of EU regulators and HTA bodies published: Tafuri et al, Br J Clin Pharmacol (2016):
- Studied population, comparator, endpoints, overall package for E and S, other study design characteristics



Qualification of novel methodologies and biomarkers

Vision: Speed up/optimise drug development and utilisation, improve public health

Procedure to guide the development of new more efficient ways to develop drugs, e.g. development of new endpoints for clinical trials

Examples:

- Methods to predict toxicity; IC to enrich a patient population for a clinical trial: Volume of certain brain structures and level of certain biochemicals in the cerebrospinal fluid for trials in Alzheimer's disease
- Surrogate clinical endpoints: new sensitive scales to measure efficacy of a new drug instead of hard clinical endpoints
- Patient and caregiver reported outcomes Guidance to R&D programmes: Scientific Advice and the PRIME network



Qualification of Novel Methodologies for drug development

CHMP Qualification Advice on future protocols and methods for further method development towards qualification.

CHMP Qualification Opinion on the acceptability of a specific use of the proposed method (e.g. use of a biomarker) in a research and development (R&D) context (non-clinical or clinical studies), based on the assessment of submitted data.

Who can apply? Consortia, Networks, Public / Private partnerships, Learned societies, Pharmaceutical industry.

122 procedures since start in 2008



Modelling and simulation- regulatory value

Early: Enable early informed discussion with sponsors regarding study designs, endpoints, dose regimens, paediatric questions, data needed to support benefit risk decisions

At MAA: Support benefit risk decisions by investigating uncertainties & untested scenarios, and their clinical consequences

Translate benefit risk from the population to individual

Inform SmPC especially for special populations

Support Subgroup analysis

Post Marketing: Inform the contents of the RMP

Lifecycle transpagemeent of AproducterIME network



Eligibility to PRIority Medicines (PRIME) scheme

Legal base-accelerated assessment

(Recital 33 and Article 14(9) of Regulation (EC) No 726/2004)



Medicinal products of major public health interest and in particular from the viewpoint of therapeutic innovation.

- Potential to address to a significant extent an unmet medical need
- Scientific justification, based on data and evidence available from nonclinical and clinical development, to address the UMN.


No satisfactory method or if method exists, bring a major therapeutic advantage

Introducing new methods or improving existing ones

> Meaningful improvement of efficacy (impact on onset, duration, improving morbidity, mortality)



Entry points PRIME eligibility and required evidence





Features of the PRIME scheme

Early access tool, supporting patient access to innovative medicines.




- Written confirmation of PRIME eligibility and potential for accelerated assessment;
 - Early CHMP Rapporteur appointment during development;
- Kick off meeting with multidisciplinary expertise from EU network;
- Enhanced scientific advice at key development milestones/decision points;
- EMA dedicated contact point;

Guidance to R&D programmes: Scientific Advice and the PRIME network for SMEs and academics on Scientific Advice and the PRIME network

PRIME eligibility recommendations adopted by 25 January 2018

EUROPEAN MEDICINES AGENCY





Take home message- Scientific Advice and PRIME

- Key tool to promote the collection of robust data on the benefits and risks of medicines
- Benefits patients as it promotes the generation of robust data and protects them from participating in badly designed or irrelevant clinical trials
- Key platform for our collaboration with health technology assessment (HTA) bodies which aims to facilitate patients' access to new medicines
- Central activity to stimulate innovation
- Regulatory incentive via PRIME is possible for medicinal products of major public health interest and in particular from the viewpoint of therapeuticarinnovations and the PRIME network



Thank you for your attention

Further information

Stiina.aarum@ema.europa.eu

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact





Backup/extra slides

Guidance to R&D programmes: Scientific Advice and the PRIME network



Transparency

Publication of monthly reports

- Broad characteristics
- Active substance (for eligible products only)
- High-level statistics




Guidance to R&D programmes: Scientific Advice and the PRIME network

List of products granted eligibility to PRIME





PRIME webpage and supporting documents



Guidance to R&D programmes: Scientific Advice and the PRIME network

	çı
PRIME - PRIORITY ME	DICINE
Paving the way for promising medicines for patients	I Highle aims at providing long top faster by optimit
Why PECHL is exceeded by a profession of the methods in the second state of the second states are also be a lead to be added and and added and and a second states are also be a lead of the second of added and a second states are also be added and added and added and a method states are also be added and second a lead of the second second states are also be added and second a lead of the second second states are also be added and second a lead of the second second states are also be added and second a lead of the second se	And Control of the Co
Benefitz of PRIME POR PATIENTE FOR PERSONER DEVELOPERE	PREME: In D
A future or fund time. The address a close fundations that address a close future time time address a close future time time address a close future time time time address a close future time time time time time time time tim	fruinnery doo so mailaite straing doo to adfame file startig a major therepeakly a to jatiens.
Investing regulatory regularizations. 8 B accompact Academics to food 1 provide the granitations 1 provide the provide setting. 1 provide setting setting setting setting setting setting setting setting setting 1 provide setting settin	Anterval Appent of The development of medicine, even anterative and cost finally patients' as
Q&A ,	
templat	-
applicat	
form fo)r

Factsheet in lay language

EUROPEAN DEPOCING ACTIVITY THE PROVINCE	
Inversion information descent and Development Report Development European Medicines Agency Guiddance for applicants seeking access to PRIME scheme https://www.communication.com/communication/ information/communication/communication/communication/communication/ information/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/ https://www.communication/communication/communication/communication/ https://www.communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/communication/communication/ https://www.communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication/communication	
seeking access to PRIME scheme The policy investor biologues quelles the appliants wing super through the IRM biologues and the second scheme of PRIME 2 special and scheme of poly- tication and the optimizer of the second scheme of the special manual scheme of the poly-through the reflect are through the special manual and scheme of the poly-through the scheme of the special manual scheme of the poly-through the reflect are through the special manual and scheme of the poly-through the scheme of the special manual and scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special scheme of the special manual scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of the special scheme of t	
Action any low. The palatox dis registers the same and factors of PERE. It products as near-year of the product is often approx of the register to soften any palatox to unspects to trappening the memory to palatox will be updated by the register of the product as a spectrum to a grant of the backets. The palatox and the updated by the register of the palatox to the update of the the palatox and the update of the palatox to the palatox to the palatox to the the palatox and the update of the palatox to the palatox to the palatox The palatox and the update of the palatox to the palatox to the palatox The palatox and the update of the palatox to the palatox to the palatox The palatox and the update of the palatox to the palatox to the palatox to the palatox the palatox and the palatox to the palatox to the palatox to the palatox the palatox and the palatox to the palatox to the palatox to the palatox the palatox and the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox to the palatox the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the palatox to the pa	
In other apport height the solute and gauge patients in transporter is pupping their signals the balance of the application with the ap	
ntenne. 18 mber 19 mai II. rogiochtor with: 18 mber 19 mai II. Status et Northe a control a suscinger al Philody Micholm (1939) Galaxya na <u>accimulat announest</u> 19 mber 19 accimulat announest 19 mber 19 mber 19 19 mber 19 mber 19 19 mber 19 mber	
trancerá any, dongas la facilhas contentual assesse ar a Pricera, Prizedas (PTIME) Galeres en <u>a contentral annecesse</u> Rancera Haccina Annec Galeres de Antoleses annas asterific adres ant annece insistence Pro naguna fuera Menutato da sur y el día included tapas, de una hacetar se send uno magan	-
Galaxies as <u>accelerated instancent</u> Consens Maderne Americ Consens for Academics Instance Execute Index and Scienced Social If you require further information on any of the includer topics, do not hastore to land your require	
European Madrona Associ Guitavice for Accelerate samples advecte and protocol assistance If you require further information on any of the included tiples, do not heatate to send your require	
If you require further information on any of the included topics, do not heatants to send your reques	
	008
II: Devil 27 See a Carey Ward y Longe Da XII a school Dagain. Nachana an 1920 (2012) 2014 (2013) Reacher La (2013) 2014 (2014) Martine and an An An Andre Martin and Anna Anna Anna Anna Anna Anna Anna	0





Early engagement in medicine development: The Innovation Task Force (ITF)


2nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency

Presented by: Falk Ehmann on 8 March 2018 Science and Innovation Office; Human Medicines Research and Development Support Division; EMA





Regulators became gatekeepers and enablers...



Clinical pharmacology & Therapeutics; Advance online publication 3 April 2013. doi:10.1038/clpt.2013.14; F Ehmann, M Papaluca Amati, T Salmonson, M Posch, S Vamvakas, R Hemmings, HG Eichler and CK Schneider



Innovation Task Force (ITF)



Multidisciplinary platform for preparatory dialogue and orientation on innovative methods, technologies and medicines




ITF objectives (ASAP):

- Assist Knowledge exchange on innovative strategies involving regulatory network
- Support drug development via early dialogue on
 - Scientific, legal and regulatory issues
 - Products, methodologies and technologies
- Address the impact of emerging therapies and technologies on current regulatory system
- Preparing for formal procedures




Users of the Innovation Task Force

Originator and the marketing authorization holder for 94 approved products evaluated, divided according to organization type




Regulatory watch: Where do new medicines originate from in the EU? Nature Reviews Drug Discovery Volume: 13, Pages: 92–93; Published online 31 January 2014



ITF users 2012-2015



Multidisciplinary ITF (internal) resources from across the Agency:





ITF (external) ITF resources from EU and beyond:

- EU regulatory network including Committees, WPs and experts
- Research and other EU Public Institutions (Karolinska, Italian Nano Centre, Max-Planck, Frauenhofer)
- **EU Institutions** e.g. Joint Research Centre, EFSA, ECHA, EDQM, DG Research, -Sante, -Growth
- Expertise from International Regulators, e.g. FDA, PMDA/MHLW, HC, Swissmedic, TGA
- International Institutions (US-Nano Characterisation Laboratory, Mayo Clinic)
- Other bodies within the EU (ECDC, Medical device authorities)



Main tasks of the Innovation Task Force (ITF)

- Coordination of ITF briefing meetings
- ATMP classification review
- Art. 57 Scientific Opinion


 \rightarrow With focus on:

Emerging therapies and technologies

e.g. Nanomedicines, Synthetic Biology, Epigenetics,
Biomaterial, Health technologies (e- and m-health)

Borderline and combination products e.g. devices, cosmetics, food

Involvement in ITF Briefing Meetings (internal and external):



Year of meetings	2013	2014	2015	2016
Number of meetings	23	27	33	41
ITF attendees	51	66	54	116
EMA attendees (non ITF)	25	32	74	106
WP experts from EU Regulatory Network	70	71	65	123
Industry attendees	109	90	98	147
Total	255	259	291	492




Impact of Innovation Task Force on other EMA procedures:

92 ITF Briefing meetings organised between 2014 – 2016, of which **80%** were submitted by **academia**, **SMEs and consortia** (ITF support focus)

- 15% are Advanced Therapies (Gene, Cell, Tissue engineered products)
- 14% consider seeking EU Orphan Drug designation (rare diseases)
- 20% consider interaction with the EMA Paediatric Committee (PDCO)
- 30% of applicants consider applying a formal scientific advice request
- 11% consider Qualification of methodology (e.g. Biomarker qualification)
- 10% consider Marketing Authorisation Application within foreseeable future



ITF Outcomes: Intel gathering and dissemination



- Awareness sessions broadcasted via EU-NTC
- Recommendations for the organisation of **workshops**, **expert meetings**
- Recommendations for **Drafting guidance**
- Input in Horizon Scanning and EU Innovation Network



Take home messages

- Regulators became gatekeepers and enablers
- The EMA is open to discuss scientific, regulatory and technical aspects of innovative developments
- The ITF is the Regulator's tool for informal early engagement and feed-back

Further information

See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9

Contact us at: ITFsecretariat@ema.europa.eu

LABORATORY OF PHARMACEUTICAL BIOTECHNOLOGY

The role of the academic experts in Scientific Advice


Prof.Dr.Apr. Dieter Deforce





EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH

ROLE OF ACADEMIC EXPERTS







- Working parties and other groups
- ▼ CHMP

Biologics Working Party

Patients' and Consumers' Working Party

Healthcare Professionals' Working Party

Quality Working Part

Safety Working Part

Scientific Advice Working Party

Biosimilar Medicinal Products Working Party

Biostatistics Working Party

Blood Products Working Party

Cardiovascular Working Party

Central Nervous System Working Party

Excipients Drafting Group

Gastroenterology Drafting Group

Infectious Diseases Working Party

Inter-Committee Scientific Advisory Group on Oncology

(Invented) Name Review Group

Oncology Working Party

Pharmacogenomics Working Party Pharmacokinetics Working Party

Radiopharmaceuticals Drafting Group

Respiratory Drafting Group

Rheumatology / Immunology Working Party

Vaccines Working Party

Scientific Advisory Group on Cardiovascular Issues

Scientific Advisory Group on Antiinfectives

Scientific Advisory Group on Diabetes / Endocrinology

Scientific Advisory Group on HIV/Viral Diseases

Scientific Advisory Group on Neurology

Scientific Advisory Group on Psychiatry

Scientific Advisory Group on Vaccines

Working Group on Quality Review of Documents

Expert Group on 3Rs

Active Substance Master File Working Group

Geriatric Expert Group

SmPC Advisory Group

Modelling and Simulation Working Group

Assessor

ROLE OF (ACADEMIC) EXPERTS

- As member of the SAWP
- As assessor
 - Conflict of Interest
- As member of CHMP
- As member of Working parties and other groups





	,	·,			
How the committees	▶ Home ▶ Committees ▶ Working parties and other groups ▶ CHMP				
work	CHMP: Wo	orking parties ar	nd other g	roups	
СНМР	The Committee fo	r Modicinal Products for	Human Ilco ((HMD) oct:	
CVMP	The Committee for Medicinal Products for Human Use (CHMP) est number of working parties at the beginning of each three-year ma working parties have expertise in a particular scientific field, and				
PRAC	members selected from the list of European experts maintained				



Home Find medicine	Human regulatory Veterinary regulatory Committees News & events Partners				
How the committees	Home ► Committees ► Working parties and other groups ► CHMP				
work	CHMP: Working parties and other groups				
СНМР	The Committee for Medicinal Products for Human Use (CHMP) establishes a				
CVMP	number of working parties at the beginning of each three-year mandate. The				



- Academic Experts and Non-Academic Experts and in-between
- Experts in different fields:
 - Quality: biologics and non-biologics
 - Non-clinical
 - Clinical
 - Statistics







- Internal experts:
 - Staff National Agencies
 - Some also clinical appointments
 - Some also academic appointments
- External experts:
 - Academic appointments
 - Clinical appointments





s nts

THE MAKING OF A SCIENTIFIC ADVICE

- Two member coordinators appointed per advice
- Coordinators involve (several) internal/external experts
 - Provide responses to questions
- Coordinators draft each a first report
- Discussion at SAWP
 - Two outcomes:
 - Joint Report OR Discussion Meeting









6

THE MAKING OF A SCIENTIFIC ADVICE (CONT)

- Discussion meeting:
 - Involve additional SAWP members
 - Involvement of assessors and additional (external/academic) experts
 - Patient Representatives







THE MAKING OF A SCIENTIFIC ADVICE (CONT)

- **Joint Report:**
 - Involve other Working parties and groups
 - Consensus between coordinators/SAWP group/assessors
 - Peer Review
 - Discussion at CHMP
 - Final advice letter







EXTERNAL EXPERTS: WIN-WIN

- **SAWP:**
- Clinical practice
- Recent scientific

developments







External/academic: Latest developments industry/trials Regulatory framework

Ewa Balkowiec Iskra Ole Weis Bjerrum Brigitte Bloechl-Daum David Brown Fernando de Andrés Trelles Minne Casteels Dieter Deforce Pierre Demolis Paolo Foggi Christian Gartner Kolbeinn Gudmundsson Kirstine Moll Harboe Robert James Hemmings (Chair) Angeles Alonso Garcia Karl-Heinz Hue **Brigitte Keller-Stanis** Sheila Killalea Rune Kjeken Armin Koch Andrea Laslop Romaldas Mačiulaitis Armando Magrelli Peter Mol Alexandre Moreau Jan Mueller-Berghaus Koenraad Norga

Daniel O'Connor Maura O'Donovan Johannes Hendrikus Ovelgonne Markku Pasanen Mair Powell Livia Puljak Jens Reinhardt Mario Miguel Rosa Elmer Schabel Jan Sjöberg

Olli Tenhunen Kerstin Wickström Adriana Andrić Dina Apele-Freimane **Caroline** Auriche-Benichou Nicolas Beix Carin Bergquist Susan Cole André Elferink **Blanca Garcia-Ochoa** na Gudmundsdottir/ Marion Haberkamp Walter Janssens arin Janssen van Doorn

Filip Josephson Andreas Kirisits Juha Kolehmainen Katerina Kopeckova Stephan Lehr Herve Le Louet

João Manuel Lopes de Oliveira Serena Marchetti Dana Gabriela Marin James McBlane Jeanette McCallion Martin Mengel Susan Morgan Odoardo Maria Olimpieri Karri Penttila Anja Schiel Audrey Sultana Johanna Wernsperger Mogens Westergaard Elena Wolff-Holz









